Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
58
AUPH Quote, Financials, Valuation and Earnings
Last price:
$14.32
Seasonality move
:
9.05%
Day range:
$14.12 - $14.50
52-week range:
$6.55 - $16.54
Dividend yield:
0%
P/E ratio:
25.66x
P/S ratio:
7.64x
P/B ratio:
5.19x
Volume:
519.9K
Avg. volume:
906.3K
1-year change:
82.97%
Market cap:
$1.9B
Revenue:
$235.1M
EPS (TTM):
$0.56
Analysts' Opinion
-
Consensus RatingAurinia Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.67, Aurinia Pharmaceuticals, Inc. has an estimated upside of 15.74% from its current price of $14.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $14.40.
Fair Value
-
According to the consensus of 7 analysts, Aurinia Pharmaceuticals, Inc. has 15.74% upside to fair value with a price target of $16.67 per share.
AUPH vs. S&P 500
-
Over the past 5 trading days, Aurinia Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aurinia Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aurinia Pharmaceuticals, Inc. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Aurinia Pharmaceuticals, Inc. reported revenues of $73.5M.
Earnings Growth
-
Aurinia Pharmaceuticals, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Aurinia Pharmaceuticals, Inc. reported earnings per share of $0.23.
Enterprise value:
1.6B
EV / Invested capital:
--
Price / LTM sales:
7.64x
EV / EBIT:
16.73x
EV / Revenue:
6.11x
PEG ratio (5yr expected):
--
EV / Free cash flow:
13.50x
Price / Operating cash flow:
16.88x
Enterprise value / EBITDA:
13.94x
Gross Profit (TTM):
$236.4M
Return On Assets:
14.77%
Net Income Margin (TTM):
29.28%
Return On Equity:
21.42%
Return On Invested Capital:
17.52%
Operating Margin:
41.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $158.9M | $220.4M | $265.8M | $67.8M | $73.5M | |
| Gross Profit | $148M | $192.3M | $236.4M | $61.7M | $65.3M | |
| Operating Income | -$93M | -$15.7M | $97.1M | $16.3M | $30.7M | |
| EBITDA | -$85.9M | $3.8M | $116.5M | $21.2M | $35.5M | |
| Diluted EPS | -$0.54 | -$0.16 | $0.56 | $0.10 | $0.23 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $329.2M | $459.7M | $426.5M | $440.5M | $438.7M | |
| Total Assets | $360.1M | $488.3M | $555M | $549.4M | $527.5M | |
| Current Liabilities | $37.5M | $41.8M | $73.9M | $78.6M | $76.2M | |
| Total Liabilities | $61.9M | $64.9M | $163.1M | $161.4M | $161.8M | |
| Total Equity | $298.2M | $423.4M | $391.9M | $388M | $365.8M | |
| Total Debt | $7.8M | $7.3M | $92.2M | $86.8M | $77.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.9M | $29M | $120.6M | $17M | $45M | |
| Cash From Investing | -$2M | -$6.2M | $42.5M | -$10.5M | -$14M | |
| Cash From Financing | $1.1M | -$31.5M | -$128M | -$2.8M | -$10.4M | |
| Free Cash Flow | -$36.6M | $28.7M | $120.4M | $16.8M | $45M | |
AUPH
Sector
Market Cap
$1.9B
$25.2M
Price % of 52-Week High
87.06%
49.83%
Dividend Yield
0%
0%
Shareholder Yield
6.96%
-1.77%
1-Year Price Total Return
82.97%
-21.9%
Beta (5-Year)
1.504
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$14.40
200-day SMA
Buy
Level
$12.06
Bollinger Bands (100)
Buy
Level
12.65 - 15.97
Chaikin Money Flow
Sell
Level
-159.1M
20-day SMA
Sell
Level
$14.56
Relative Strength Index (RSI14)
Sell
Level
43.19
ADX Line
Sell
Level
13.84
Williams %R
Neutral
Level
-79.2593
50-day SMA
Sell
Level
$15.18
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
406.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2738)
Buy
CA Score
(Annual)
Level (0.6792)
Buy
Beneish M-Score
(Annual)
Level (-2.4402)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-8.9994)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.
Stock Forecast FAQ
In the current month, AUPH has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AUPH average analyst price target in the past 3 months is $16.67.
-
Where Will Aurinia Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aurinia Pharmaceuticals, Inc. share price will rise to $16.67 per share over the next 12 months.
-
What Do Analysts Say About Aurinia Pharmaceuticals, Inc.?
Analysts are divided on their view about Aurinia Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aurinia Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Aurinia Pharmaceuticals, Inc.'s Price Target?
The price target for Aurinia Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $16.67 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AUPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aurinia Pharmaceuticals, Inc. is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AUPH?
You can purchase shares of Aurinia Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aurinia Pharmaceuticals, Inc. shares.
-
What Is The Aurinia Pharmaceuticals, Inc. Share Price Today?
Aurinia Pharmaceuticals, Inc. was last trading at $14.32 per share. This represents the most recent stock quote for Aurinia Pharmaceuticals, Inc.. Yesterday, Aurinia Pharmaceuticals, Inc. closed at $14.40 per share.
-
How To Buy Aurinia Pharmaceuticals, Inc. Stock Online?
In order to purchase Aurinia Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AUPH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AUPH
Sector
P/E ratio
25.66x
23.30x
PEG ratio
--
-0.01x
P/B ratio
5.19x
1.78x
Price / LTM sales
7.64x
1.55x
Growth Metrics
AUPH
Sector
Revenue growth
8.41%
3.69%
Earnings growth
135.53%
9.95%
Revenue (5-year growth)
274.78%
6.38%
Earnings forecast
$0.22
-$0.19
Profitability
AUPH
Sector
Profitability FY 2024
$206.9M
$2.6M
Return on invested capital
17.52%
-33.25%
Return on assets
14.77%
-29.67%
Return on equity
21.42%
-38.66%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
AUPH
Sector
Total cash
$351.8M
$25.1M
Short term investments
$275M
$24M
Total assets
$550.6M
$72.5M
Long term debt
$77.2M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
